Nurix Therapeutics, Inc. (NRIX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Liquidia Corp.

Marinus Pharmaceuticals, Inc.

SIGA Technologies, Inc.

Zymeworks, Inc.

ARS Pharmaceuticals, Inc.

Nurix Therapeutics, Inc.

Cullinan Therapeutics, Inc.

Icosavax, Inc.

Oculis Holding AG

Biomea Fusion, Inc.

Procaps Group SA

Why is Nurix Therapeutics, Inc. ?

With a fall in Net Sales of -49.61%, the company declared Very Negative results in May 26

The company has declared negative results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Lowest at USD -293.69 MM
NET SALES(Q) At USD 9.04 MM has Fallen at -49.61%
ROCE(HY) Lowest at -80.3%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 141.11%, its profits have fallen by -36.6%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -1.64% over the previous quarter and currently hold 4.67% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Nurix Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Nurix Therapeutics, Inc.

141.11%

1.04

62.33%

S&P 500

21.51%

1.63

13.19%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

36.35%

EBIT Growth (5y)

-219.10%

EBIT to Interest (avg)

-164.05

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.07

Sales to Capital Employed (avg)

0.22

Tax Ratio

0.41%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.82

EV to EBIT

-3.25

EV to EBITDA

-3.48

EV to Capital Employed

-18.06

EV to Sales

11.05

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-49.09%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

NET PROFIT(HY)

Higher at USD -176.71 MM

-32What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -293.69 MM

NET SALES(Q)

At USD 9.04 MM has Fallen at -49.61%

ROCE(HY)

Lowest at -80.3%

RAW MATERIAL COST(Y)

Grown by 35.46% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -95.72 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.25 times

OPERATING PROFIT(Q)

Lowest at USD -90.35 MM

PRE-TAX PROFIT(Q)

Lowest at USD -89.81 MM

NET PROFIT(Q)

Lowest at USD -89.53 MM

Here's what is not working for Nurix Therapeutics, Inc.

Net Sales

At USD 9.04 MM has Fallen at -49.61%

over average net sales of the previous four periods of USD 17.94 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -293.69 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -90.35 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -89.81 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -89.81 MM has Fallen at -21.97%

over average net sales of the previous four periods of USD -73.63 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -89.53 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit

At USD -89.53 MM has Fallen at -21.29%

over average net sales of the previous four periods of USD -73.82 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -95.72 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 3.25 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 35.46% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales